RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.

Answers from the Lab

Nov 14, 2023•11 min•Ep. 260

--:--

Listen in podcast apps:

Apple Podcasts

Spotify

Download

Listen to this episode in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.

Speaker 2: (00:32)
Could you provide a brief background about yourself?

Speaker 2: (01:12)
Would you give us an overview of the PM3CX test?

Speaker 2: (03:02)
Which patients should have this testing?

Speaker 2: (05:14)
Is this test qualitative and RNA?

Speaker 2: (06:35)
After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?

Speaker 2: (08:09)
For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?

Speaker 2: (09:04)

Are there any other insights about this test that you'd like to share?

For the best experience, listen in Metacast app for iOS or Android